FDA Approves GE’s Lunar iDXA

The U.S. Food and Drug Administration has approved GE Healthcare’s Lunar iDXA.


Designed to detect, diagnose and monitor treatment for osteoporosis, GE’s iDXA also offers the ability to simultaneously assess total body composition and regional distribution of fat and muscle mass.

Capable of measuring patients up to 400 lbs, this latest leap in investigative technology offers us a unique chance to better understand the underlying and previously unseen role of sarcopenia and its potential impact on obesity (sarcopenic obesity).

To locate the nearest machine to you, please click here